Brief Summary
The purpose of this study is to determine the recommended Phase 2 dose of zanzalintinib when given in combination with paclitaxel in patients with recurrent high-grade uterine cancer. Other objectives include overall safety and tolerability as well as rates of response.
Protocol Interventions
Drug: Zanzalintinib, Drug: Paclitaxel